Severity
Critical
FDA Drug recall · Reported January 17, 2024
Defective Container: powder may leak out of the pouch
InvaGen Pharmaceuticals, Inc. recalled Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box, Rx Only, Manufac… - a critical-severity action.
Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box, Rx Only, Manufac… was recalled by InvaGen Pharmaceuticals, Inc. in January 17, 2024. Reason: Defective Container: powder may leak out of the pouch. Check the official notice for the remedy. Verify recall #D-0220-2024 with the FDA Drug before acting.
The recall
InvaGen Pharmaceuticals, Inc. issued this critical-severity FDA Drug recall-Defective Container: powder may leak out of the pouch.
Sourced from official FDA Drug enforcement records. Verify recall #D-0220-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0220-2024) was formally reported on January 17, 2024, with the manufacturer initiating the action on November 17, 2023. It is classified under Critical severity (Class I), with a current status of Completed. InvaGen Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Central Islip, NY. Federal records list the affected scope as 1240 boxes.
The documented reason for this recall is: Defective Container: powder may leak out of the pouch Distribution data in the federal record shows the product reached: Nationwide within the United States. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
1240 boxes
Related Recalls
6
5 from same agency
Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box, Rx Only, Manufactured by: InvaGen Pharmaceuticals, Inc., (a subsidiary of Cipla Ltd.), Hauppauge, NY, 11788, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, NDC 69097-964-53
Defective Container: powder may leak out of the pouch
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Completed |
| Recall number | D-0220-2024 |
| Date reported | January 17, 2024 |
| Date initiated | November 17, 2023 |
| Recalling firm | InvaGen Pharmaceuticals, Inc. |
| Firm location | Central Islip, NY |
| Affected scope | 1240 boxes |
| Distribution | Nationwide within the United States |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 17, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.